TSRYF (TSRYF)

Tirlay Brands shares have declined 33% year to date.

Tilray Brands recently reported a quarterly loss of $0.24 per share with revenue falling short of market expectations, while also completing its acquisition of UK-based Lyphe Group to expand its medical cannabis footprint and digital health capabilities in that market.

Tilray stock reaction to U.S. policy news and new Carlsberg partnership Tilray Brands (TLRY) is back in focus after U.S. cannabis reclassification headlines, a fresh multi-year partnership with Carlsberg, and a recent share price decline even as many cannabis peers gained.

Tilray Brands has reported fresh quarterly numbers and continues to reposition itself as a global cannabis and beverage company. What the latest figures reveal about the business model – and what investors in the US and Europe should know.

Tilray Brands’ fair value estimate currently stands at $10.04, with the latest update keeping this price target unchanged. Even with several analysts trimming their targets in both US$ and C$, others are turning more constructive after the partial cannabis rescheduling order and the BrewDog ...